Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.
Duchenne muscular dystrophy (DMD), the commonest form of muscular dystrophy, is caused by lack of dystrophin. One of the most promising therapeutic approaches is antisense-mediated elimination of frame-disrupting mutations by exon skipping. However, this approach faces two major hurdles: limited app...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797084089202769920 |
|---|---|
| author | Aoki, Y Yokota, T Nagata, T Nakamura, A Tanihata, J Saito, T Duguez, S Nagaraju, K Hoffman, E Partridge, T Takeda, S |
| author_facet | Aoki, Y Yokota, T Nagata, T Nakamura, A Tanihata, J Saito, T Duguez, S Nagaraju, K Hoffman, E Partridge, T Takeda, S |
| author_sort | Aoki, Y |
| collection | OXFORD |
| description | Duchenne muscular dystrophy (DMD), the commonest form of muscular dystrophy, is caused by lack of dystrophin. One of the most promising therapeutic approaches is antisense-mediated elimination of frame-disrupting mutations by exon skipping. However, this approach faces two major hurdles: limited applicability of each individual target exon and uncertain function and stability of each resulting truncated dystrophin. Skipping of exons 45-55 at the mutation hotspot of the DMD gene would address both issues. Theoretically it could rescue more than 60% of patients with deletion mutations. Moreover, spontaneous deletions of this specific region are associated with asymptomatic or exceptionally mild phenotypes. However, such multiple exon skipping of exons 45-55 has proved technically challenging. We have therefore designed antisense oligo (AO) morpholino mixtures to minimize self- or heteroduplex formation. These were tested as conjugates with cell-penetrating moieties (vivo-morpholinos). We have tested the feasibility of skipping exons 45-55 in H2K-mdx52 myotubes and in mdx52 mice, which lack exon 52. Encouragingly, with mixtures of 10 AOs, we demonstrated skipping of all 10 exons in vitro, in H2K-mdx52 myotubes and on intramuscular injection into mdx52 mice. Moreover, in mdx52 mice in vivo, systemic injections of 10 AOs induced extensive dystrophin expression at the subsarcolemma in skeletal muscles throughout the body, producing up to 15% of wild-type dystrophin protein levels, accompanied by improved muscle strength and histopathology without any detectable toxicity. This is a unique successful demonstration of effective rescue by exon 45-55 skipping in a dystrophin-deficient animal model. |
| first_indexed | 2024-03-07T01:50:31Z |
| format | Journal article |
| id | oxford-uuid:99eeec27-6cec-4ae8-b78a-3e6efe3c9ae0 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:50:31Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:99eeec27-6cec-4ae8-b78a-3e6efe3c9ae02022-03-27T00:17:50ZBodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:99eeec27-6cec-4ae8-b78a-3e6efe3c9ae0EnglishSymplectic Elements at Oxford2012Aoki, YYokota, TNagata, TNakamura, ATanihata, JSaito, TDuguez, SNagaraju, KHoffman, EPartridge, TTakeda, SDuchenne muscular dystrophy (DMD), the commonest form of muscular dystrophy, is caused by lack of dystrophin. One of the most promising therapeutic approaches is antisense-mediated elimination of frame-disrupting mutations by exon skipping. However, this approach faces two major hurdles: limited applicability of each individual target exon and uncertain function and stability of each resulting truncated dystrophin. Skipping of exons 45-55 at the mutation hotspot of the DMD gene would address both issues. Theoretically it could rescue more than 60% of patients with deletion mutations. Moreover, spontaneous deletions of this specific region are associated with asymptomatic or exceptionally mild phenotypes. However, such multiple exon skipping of exons 45-55 has proved technically challenging. We have therefore designed antisense oligo (AO) morpholino mixtures to minimize self- or heteroduplex formation. These were tested as conjugates with cell-penetrating moieties (vivo-morpholinos). We have tested the feasibility of skipping exons 45-55 in H2K-mdx52 myotubes and in mdx52 mice, which lack exon 52. Encouragingly, with mixtures of 10 AOs, we demonstrated skipping of all 10 exons in vitro, in H2K-mdx52 myotubes and on intramuscular injection into mdx52 mice. Moreover, in mdx52 mice in vivo, systemic injections of 10 AOs induced extensive dystrophin expression at the subsarcolemma in skeletal muscles throughout the body, producing up to 15% of wild-type dystrophin protein levels, accompanied by improved muscle strength and histopathology without any detectable toxicity. This is a unique successful demonstration of effective rescue by exon 45-55 skipping in a dystrophin-deficient animal model. |
| spellingShingle | Aoki, Y Yokota, T Nagata, T Nakamura, A Tanihata, J Saito, T Duguez, S Nagaraju, K Hoffman, E Partridge, T Takeda, S Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. |
| title | Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. |
| title_full | Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. |
| title_fullStr | Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. |
| title_full_unstemmed | Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. |
| title_short | Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. |
| title_sort | bodywide skipping of exons 45 55 in dystrophic mdx52 mice by systemic antisense delivery |
| work_keys_str_mv | AT aokiy bodywideskippingofexons4555indystrophicmdx52micebysystemicantisensedelivery AT yokotat bodywideskippingofexons4555indystrophicmdx52micebysystemicantisensedelivery AT nagatat bodywideskippingofexons4555indystrophicmdx52micebysystemicantisensedelivery AT nakamuraa bodywideskippingofexons4555indystrophicmdx52micebysystemicantisensedelivery AT tanihataj bodywideskippingofexons4555indystrophicmdx52micebysystemicantisensedelivery AT saitot bodywideskippingofexons4555indystrophicmdx52micebysystemicantisensedelivery AT duguezs bodywideskippingofexons4555indystrophicmdx52micebysystemicantisensedelivery AT nagarajuk bodywideskippingofexons4555indystrophicmdx52micebysystemicantisensedelivery AT hoffmane bodywideskippingofexons4555indystrophicmdx52micebysystemicantisensedelivery AT partridget bodywideskippingofexons4555indystrophicmdx52micebysystemicantisensedelivery AT takedas bodywideskippingofexons4555indystrophicmdx52micebysystemicantisensedelivery |